113 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
49
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Jagiellonian University Medical College
6
Metabolism study and biological evaluation of bosentan derivatives.
University of Perugia
47
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Jagiellonian University Medical College
7
Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity.
Southeast University
40
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).
Glaxosmithkline
59
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
Actelion Pharmaceuticals
95
Designed multiple ligands. An emerging drug discovery paradigm.
Organon Laboratories
38
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
Encysive Pharmaceuticals
32
Selective optimization of side activities: another way for drug discovery.
Prestwick Chemical
41
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
Bristol Myers Squibb
11
Potent and selective ET-A antagonists. 2. Discovery and evaluation of potent and water soluble N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.
Tanabe Seiyaku
83
Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308).
Bristol Myers Squibb
19
Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
Rh£Ne-Poulenc Rorer
14
Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties.
Warner-Lambert
50
Synthesis and structure-activity relationships of 2-substituted D-tryptophan-containing peptidic endothelin receptor antagonists: importance of the C-2 substituent of the D-tryptophan residue for endothelin A and B receptor subtype selectivity.
Tsukuba Research Institute
10
Endothelin-1 analogues substituted at both position 18 and 19: highly potent endothelin antagonists with no selectivity for either receptor subtype ETA or ETB.
Takeda Chemical Industries
45
Structure-activity relationships of C-terminal endothelin hexapeptide antagonists.
Warner-Lambert
9
Cyclic pentapeptide endothelin antagonists with high ETA selectivity. Potency- and solubility-enhancing modifications.
TBA
27
Endothelin antagonists: discovery of EMD 122946, a highly potent and orally active ETA selective antagonist.
Merck
23
Discovery of Ro 48-5695: A potent mixed endothelin receptor antagonist optimized from bosentan
TBA
12
Design and synthesis of nonpeptidal endothelin receptor antagonists based on the structure of a cyclic pentapeptide
TBA
8
Synthesis of 2-substituted d-tryptophan-containing peptide derivatives with endothelin receptor antagonist activity
TBA
8
Development and evaluation of endothelin-A receptor (radio)ligands for positron emission tomography.
University Hospital Mu£Nster
15
Synthesis and pharmacological activity of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acids as selective ET(A) antagonists.
St. John'S University
1
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical and Public Health Institute
7
PET-compatible endothelin receptor radioligands: synthesis and first in vitro and in vivo studies.
University Hospital M£Nster
4
A Novel Class of Non-Peptidic Endothelin Antagonists Isolated from the Medicinal Herb Phyllanthus niruri
TBA
25
Amide bond surrogates: A study in thiophenesulfonamide based endothelin receptor antagonists
TBA
13
Search for surrogates: A study of endothelin receptor antagonist structure activity relationships
TBA
11
γ-Carbamate butenolide analogues as potent ETA selective endothelin receptor antagonists and prodrugs
TBA
24
2-Aryloxycarbonylthiophene-3-sulfonamides: Highly potent and etA selective endothelin receptor antagonists
TBA
13
1,4-Diaryl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acids as endothelin receptor antagonists
TBA
12
RES-701-1/endothelin-1 hybrid peptide having a potent binding activity for type B receptor
TBA
28
Synthesis and structure-activity relationships of 9-substituted acridines as endothelin-A receptor antagonists
TBA
73
Halogen substitution at the isoxazole ring enhances the activity of N-(isoxazolyl)sulfonamide endothelin antagonists
TBA
15
Discovery of substituted 8,9-dicarboxyldibenzo [2,3:5,6] bicyclo [5.2.0] nonan-4-ones with moderate binding affinity to the endothelin ETA and ETB receptors
TBA
12
Potent dual antagonists of endothelin and angiotensin II receptors derived from α-phenoxyphenylacetic acids (Part III)
TBA
13
Design of C-terminal peptide antagonists of endothelin: structure-activity relationships of ET-[16–21, D-His16]
TBA
11
Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor.
Abbott Laboratories
4
Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies.
Abbott Laboratories
9
Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives.
Shanghai Institute of Materia Medica
7
Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies.
Covx Research
103
Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.
Actelion Pharmaceuticals
52
Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists.
University of Innsbruck
19
Structure-activity relationships of a novel class of endothelin receptor selective antagonists; 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridines.
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
57
The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.
Actelion Pharmaceuticals
20
Structure-Activity relationships of 2-substituted 5,7-Diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acids as a novel class of endothelin receptor antagonists.
Tsukuba Research Institute
5
Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.
Bristol Myers Squibb
97
Structure-activity relationships of a novel class of endothelin-A receptor antagonists and discovery of potent and selective receptor antagonist, 2-(benzo[1,3]dioxol-5-yl)-6-isopropyloxy-4-(4-methoxyphenyl)-2H-chromene-3-carboxylic acid (S-1255). 1. Study on structure-activity relationships and bas
Shionogi
17
Biphenylsulfonamide endothelin receptor antagonists. Part 3: structure-activity relationship of 4'-heterocyclic biphenylsulfonamides.
Bristol Myers Squibb
24
The design and synthesis of a novel series of indole derived selective ET(A) antagonists.
Pfizer
48
Pyridine alkaloids with activity in the central nervous system.
University of Auckland
23
Modifications and structure-activity relationships at the 2-position of 4-sulfonamidopyrimidine derivatives as potent endothelin antagonists.
Tanabe Seiyaku
20
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.
Abbott Laboratories
60
Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.
Tanabe Seiyaku
29
Isoindolines: a new series of potent and selective endothelin-A receptor antagonists.
Novartis Institute For Biomedical Research
28
Potent nonpeptide endothelin antagonists: synthesis and structure-activity relationships of pyrazole-5-carboxylic acids.
Hoechst Marion Roussel
14
Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists.
Bristol Myers Squibb
7
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
Centre Hospitalier Universitaire Vaudois (Chuv)
28
Nonpeptide endothelin antagonists: from lower affinity pyrazol-5-ols to higher affinity pyrazole-5-carboxylic acids.
Hoechst Marion Roussel
6
Synthesis and endothelin receptor binding activity of synthetic analogues of RES-1149-2.
Iowa State University
77
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
Actelion Pharmaceuticals
26
Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.
Abbott Laboratories
27
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity.
Abbott Laboratories
24
Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist.
Basf
26
Benzofuro[3,2-b]pyridines as mixed ET(A)/ET(B) and selective ET(B) endothelin receptor antagonists.
Merck
86
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
Shanghaitech University
4
Stereoselective synthesis of a novel and bifunctional endothelin antagonist, IRL 3630.
Takarazuka Research Institute
26
Discovery of IRL 3461: a novel and potent endothelin antagonist with balanced ETA/ETB affinity.
Takarazuka Research Institute
13
Endothelin antagonists: evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster.
Merck
47
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
Abbott Laboratories
38
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
Abbott Laboratories
34
Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist.
Immunopharmaceutics
46
Structure-activity relationships of N2-aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists.
Immunopharmaceutics
83
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
Warner-Lambert
29
Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists.
Abbott Laboratories
64
2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
Abbott Laboratories
23
Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists.
Basf
16
Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption.
Abbott Laboratories
25
Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile.
Abbott Laboratories
7
1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists.
Smithkline Beecham Pharmaceuticals
17
Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists.
Warner-Lambert
52
Structure-activity relationships of the potent combined endothelin-A/endothelin-B receptor antagonist Ac-DDip16-Leu-Asp-Ile-Ile-Trp21: development of endothelin-B receptor selective antagonists.
Warner-Lambert
65
Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists.
Tsukuba Research Institute
24
Design, synthesis and evaluation of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acid derivatives as ET
St. John'S University
17
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.
Duquesne University
9
Inhibition of the enzymatic activity of heme oxygenases by azole-based antifungal drugs.
Queen'S University
13
Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists.
Johnson & Johnson Pharmaceutical